ID
45527
Description
Principal Investigator: Robert West, MD, PhD, Stanford School of Medicine, Department of Pathology, Stanford, CA USA MeSH: Ameloblastoma,SMO protein, human,BRAF protein, human https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000739 RNA-seq data from two cases of ameloblastoma was analyzed for candidate gene fusions and point mutations. Recurrent point mutations identified in the RNA-seq data, as well as mutations identified with limited panel targeted deep sequencing, were validated as somatic. Expanding to a larger cohort of 28, one of two activating mutations was found in 80% of cases. No recurrent gene fusions events were identified.
Link
Keywords
Versions (1)
- 12/26/22 12/26/22 - Chiara Middel
Copyright Holder
Robert West, MD, PhD, Stanford School of Medicine, Department of Pathology, Stanford, CA USA
Uploaded on
December 26, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000739 Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Subject ID, gender, age, and race of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, and name of center which conducted sequencing of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Subject ID, gender, age, and race of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, and name of center which conducted sequencing of participants with ameloblastoma and involved in the "Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas" project.
C0680251 (UMLS CUI [1,2])
C0002448 (UMLS CUI [1,2])
C0030664 (UMLS CUI [1,3])
C0025102 (UMLS CUI [1,4])
C0003738 (UMLS CUI [1,5])
C0750484 (UMLS CUI [2,1])
C0011900 (UMLS CUI [2,2])
C0680251 (UMLS CUI [3,1])
C0520510 (UMLS CUI [3,2])
C0700185 (UMLS CUI [3,3])